Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in adults with bullous pemphigoid
2023-508645-40-00Phase 3Completed
- Sponsor
- argenx
- Start
- May 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Efgartigimod PH20 SC plus prednisone with Placebo PH20 SC plus prednisone (2 arms). Primary endpoint: Complete remission off oral corticosteroids at week 36. Started May 2022; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on 2023-508645-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508645-40-00.